Endocrine Abstracts

Introduction: The humanized antibody anti-CD52+ alemtuzumab has been approved since 2014 for the treatment of relapsing-remitting multiple sclerosis (RRMS). Immune reconstitution after alemtuzumab induces thyroid autoimmunity in 34-41% of patients with RRMS, with Graves’ disease (GD) accounting for 63-65% of cases. Graves’ Orbitopathy (GO) may also occur in 13% of patients after alemtuzumab and is scarcely reported. Here we present the first case of alemtuzumab-induc...